 Robert McQueen
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 27 | 2024 | 545 | 3.590 |
Why?
| | Quality-Adjusted Life Years | 12 | 2024 | 101 | 1.890 |
Why?
| | Negotiating | 2 | 2024 | 26 | 1.780 |
Why?
| | Medicare | 2 | 2024 | 670 | 1.270 |
Why?
| | Models, Economic | 7 | 2020 | 48 | 1.210 |
Why?
| | Patient-Centered Care | 2 | 2023 | 474 | 1.150 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 3 | 2015 | 69 | 1.040 |
Why?
| | Natalizumab | 4 | 2015 | 46 | 1.030 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 372 | 1.020 |
Why?
| | Ovarian Neoplasms | 2 | 2020 | 387 | 1.000 |
Why?
| | Technology Assessment, Biomedical | 3 | 2022 | 29 | 1.000 |
Why?
| | Decision Support Techniques | 4 | 2022 | 351 | 0.970 |
Why?
| | Immunologic Factors | 3 | 2015 | 221 | 0.940 |
Why?
| | Hemophilia B | 1 | 2023 | 36 | 0.890 |
Why?
| | Hemophilia A | 1 | 2023 | 70 | 0.850 |
Why?
| | Asthma | 6 | 2023 | 2051 | 0.840 |
Why?
| | Azetidines | 1 | 2022 | 31 | 0.830 |
Why?
| | Endometriosis | 1 | 2023 | 40 | 0.820 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2018 | 498 | 0.820 |
Why?
| | Hypercholesterolemia | 1 | 2022 | 91 | 0.790 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2020 | 3250 | 0.780 |
Why?
| | Anticholesteremic Agents | 1 | 2022 | 128 | 0.740 |
Why?
| | Medication Adherence | 2 | 2015 | 537 | 0.720 |
Why?
| | Value-Based Purchasing | 1 | 2019 | 6 | 0.690 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 67 | 0.680 |
Why?
| | Academies and Institutes | 1 | 2019 | 44 | 0.670 |
Why?
| | Atherosclerosis | 1 | 2022 | 341 | 0.650 |
Why?
| | Patient Outcome Assessment | 1 | 2019 | 122 | 0.630 |
Why?
| | Health Care Costs | 2 | 2020 | 381 | 0.630 |
Why?
| | Biological Therapy | 1 | 2018 | 26 | 0.610 |
Why?
| | Telephone | 1 | 2018 | 152 | 0.570 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2022 | 665 | 0.550 |
Why?
| | United States | 13 | 2024 | 12256 | 0.540 |
Why?
| | Humans | 49 | 2024 | 115219 | 0.520 |
Why?
| | Health Benefit Plans, Employee | 1 | 2015 | 20 | 0.510 |
Why?
| | Research Design | 4 | 2024 | 933 | 0.490 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 1731 | 0.460 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2018 | 2098 | 0.440 |
Why?
| | Mass Screening | 1 | 2020 | 1011 | 0.430 |
Why?
| | Immunotherapy, Adoptive | 3 | 2019 | 194 | 0.430 |
Why?
| | Anti-Asthmatic Agents | 4 | 2018 | 350 | 0.420 |
Why?
| | Metformin | 1 | 2015 | 278 | 0.400 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 486 | 0.390 |
Why?
| | Foodborne Diseases | 2 | 2022 | 45 | 0.380 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2552 | 0.370 |
Why?
| | Costs and Cost Analysis | 3 | 2020 | 197 | 0.360 |
Why?
| | Neoplasms | 2 | 2020 | 2106 | 0.340 |
Why?
| | Diabetes Mellitus | 1 | 2017 | 909 | 0.320 |
Why?
| | Female | 19 | 2023 | 59717 | 0.290 |
Why?
| | Health Expenditures | 2 | 2019 | 171 | 0.280 |
Why?
| | Drug Therapy, Combination | 4 | 2022 | 959 | 0.270 |
Why?
| | Omalizumab | 2 | 2023 | 46 | 0.240 |
Why?
| | Genetic Therapy | 2 | 2023 | 258 | 0.230 |
Why?
| | Aged | 9 | 2024 | 19135 | 0.230 |
Why?
| | Heterocyclic Compounds, 2-Ring | 1 | 2023 | 4 | 0.220 |
Why?
| | Thiadiazoles | 1 | 2023 | 21 | 0.220 |
Why?
| | Ezetimibe | 1 | 2022 | 24 | 0.210 |
Why?
| | Stakeholder Participation | 1 | 2023 | 73 | 0.210 |
Why?
| | Decision Making | 4 | 2019 | 782 | 0.210 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 605 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2020 | 1214 | 0.200 |
Why?
| | Treatment Outcome | 9 | 2022 | 9151 | 0.200 |
Why?
| | Food Microbiology | 1 | 2021 | 57 | 0.190 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 308 | 0.190 |
Why?
| | Markov Chains | 3 | 2016 | 114 | 0.180 |
Why?
| | Models, Econometric | 2 | 2018 | 34 | 0.180 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 169 | 0.180 |
Why?
| | Patient Participation | 1 | 2024 | 360 | 0.180 |
Why?
| | Eicosapentaenoic Acid | 1 | 2020 | 28 | 0.180 |
Why?
| | Middle Aged | 13 | 2019 | 26872 | 0.180 |
Why?
| | Male | 15 | 2024 | 55811 | 0.180 |
Why?
| | Fees, Medical | 1 | 2019 | 9 | 0.170 |
Why?
| | Perception | 1 | 2022 | 311 | 0.170 |
Why?
| | Parkinson Disease | 1 | 2024 | 323 | 0.170 |
Why?
| | Cost of Illness | 3 | 2022 | 255 | 0.170 |
Why?
| | Medicaid | 1 | 2023 | 411 | 0.170 |
Why?
| | Teicoplanin | 1 | 2019 | 17 | 0.170 |
Why?
| | Adult | 12 | 2022 | 30708 | 0.160 |
Why?
| | Indazoles | 1 | 2019 | 58 | 0.160 |
Why?
| | Phthalazines | 1 | 2019 | 38 | 0.160 |
Why?
| | Early Diagnosis | 1 | 2020 | 218 | 0.160 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 61 | 0.160 |
Why?
| | Rivaroxaban | 1 | 2020 | 211 | 0.160 |
Why?
| | Antigens, CD19 | 1 | 2019 | 97 | 0.160 |
Why?
| | England | 1 | 2018 | 65 | 0.150 |
Why?
| | Piperidines | 1 | 2019 | 162 | 0.150 |
Why?
| | Open Access Publishing | 1 | 2017 | 5 | 0.150 |
Why?
| | Pilot Projects | 1 | 2022 | 1377 | 0.150 |
Why?
| | Lymphoma, B-Cell | 1 | 2019 | 86 | 0.150 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 159 | 0.150 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 1882 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2020 | 744 | 0.150 |
Why?
| | Aspirin | 1 | 2020 | 324 | 0.150 |
Why?
| | Heparin | 1 | 2019 | 222 | 0.150 |
Why?
| | Peer Review, Research | 1 | 2017 | 34 | 0.150 |
Why?
| | Data Collection | 1 | 2020 | 623 | 0.140 |
Why?
| | Dry Powder Inhalers | 1 | 2017 | 2 | 0.140 |
Why?
| | Adolescent | 8 | 2020 | 17887 | 0.140 |
Why?
| | Metered Dose Inhalers | 1 | 2017 | 14 | 0.140 |
Why?
| | Blood Glucose | 2 | 2018 | 1823 | 0.140 |
Why?
| | Quality of Life | 3 | 2024 | 2364 | 0.140 |
Why?
| | Indoles | 1 | 2019 | 306 | 0.140 |
Why?
| | Piperazines | 1 | 2019 | 313 | 0.140 |
Why?
| | Models, Statistical | 1 | 2020 | 603 | 0.140 |
Why?
| | Insurance Claim Review | 1 | 2017 | 67 | 0.140 |
Why?
| | Sepsis | 1 | 2022 | 508 | 0.140 |
Why?
| | Hematologic Neoplasms | 1 | 2018 | 136 | 0.140 |
Why?
| | Alzheimer Disease | 1 | 2021 | 436 | 0.140 |
Why?
| | Economics, Pharmaceutical | 1 | 2016 | 10 | 0.140 |
Why?
| | Medication Errors | 1 | 2017 | 89 | 0.130 |
Why?
| | Antirheumatic Agents | 1 | 2019 | 255 | 0.130 |
Why?
| | Spirometry | 1 | 2016 | 225 | 0.130 |
Why?
| | Information Dissemination | 1 | 2017 | 188 | 0.130 |
Why?
| | Telemedicine | 1 | 2024 | 665 | 0.130 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 231 | 0.130 |
Why?
| | Child, Preschool | 3 | 2020 | 9123 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2019 | 12596 | 0.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 269 | 0.130 |
Why?
| | Young Adult | 8 | 2019 | 10519 | 0.120 |
Why?
| | Hospitalization | 3 | 2022 | 1754 | 0.120 |
Why?
| | Anticoagulants | 1 | 2019 | 546 | 0.120 |
Why?
| | Eosinophils | 1 | 2016 | 281 | 0.120 |
Why?
| | Intellectual Property | 3 | 2019 | 5 | 0.120 |
Why?
| | Canada | 1 | 2015 | 323 | 0.120 |
Why?
| | Sex Factors | 2 | 2017 | 1722 | 0.110 |
Why?
| | Computer Simulation | 1 | 2018 | 879 | 0.110 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2014 | 48 | 0.110 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2014 | 54 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2018 | 385 | 0.110 |
Why?
| | Colorado | 2 | 2020 | 4099 | 0.110 |
Why?
| | Drug Costs | 3 | 2020 | 91 | 0.110 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2388 | 0.110 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 90 | 0.110 |
Why?
| | JC Virus | 1 | 2013 | 23 | 0.110 |
Why?
| | Child | 5 | 2020 | 18466 | 0.110 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1082 | 0.110 |
Why?
| | Fasting | 1 | 2014 | 242 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2019 | 836 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 1006 | 0.100 |
Why?
| | Autoantibodies | 1 | 2020 | 1353 | 0.100 |
Why?
| | Age Factors | 2 | 2017 | 2900 | 0.100 |
Why?
| | Ergocalciferols | 1 | 2012 | 11 | 0.100 |
Why?
| | Comorbidity | 2 | 2014 | 1458 | 0.100 |
Why?
| | Diabetes Complications | 1 | 2014 | 212 | 0.100 |
Why?
| | Income | 1 | 2012 | 169 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2014 | 1231 | 0.100 |
Why?
| | International Classification of Diseases | 2 | 2022 | 116 | 0.090 |
Why?
| | Diabetic Nephropathies | 1 | 2014 | 234 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2019 | 629 | 0.090 |
Why?
| | Unemployment | 1 | 2010 | 39 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 1002 | 0.090 |
Why?
| | Diagnostic Tests, Routine | 1 | 2011 | 87 | 0.090 |
Why?
| | Databases, Factual | 1 | 2015 | 1136 | 0.090 |
Why?
| | Prescription Drugs | 1 | 2012 | 116 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1481 | 0.090 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 158 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 1860 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 667 | 0.080 |
Why?
| | Epilepsy | 1 | 2012 | 277 | 0.080 |
Why?
| | Vitamin D | 1 | 2012 | 340 | 0.080 |
Why?
| | Depressive Disorder | 1 | 2010 | 333 | 0.070 |
Why?
| | Uncertainty | 2 | 2019 | 95 | 0.070 |
Why?
| | Cohort Studies | 4 | 2019 | 4917 | 0.070 |
Why?
| | Multiple Sclerosis | 1 | 2011 | 380 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2015 | 4430 | 0.070 |
Why?
| | Hemorrhage | 2 | 2020 | 618 | 0.060 |
Why?
| | Infant | 2 | 2015 | 7966 | 0.060 |
Why?
| | Neurologists | 1 | 2024 | 18 | 0.060 |
Why?
| | Recurrence | 2 | 2018 | 952 | 0.050 |
Why?
| | Stress, Psychological | 1 | 2010 | 946 | 0.050 |
Why?
| | Glatiramer Acetate | 2 | 2013 | 20 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2019 | 6358 | 0.050 |
Why?
| | Massachusetts | 1 | 2022 | 136 | 0.050 |
Why?
| | Menopause | 1 | 2023 | 271 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 57 | 0.040 |
Why?
| | Off-Label Use | 1 | 2019 | 52 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2019 | 34 | 0.040 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 66 | 0.040 |
Why?
| | Population Surveillance | 1 | 2021 | 392 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 83 | 0.040 |
Why?
| | Palliative Care | 1 | 2024 | 640 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 78 | 0.040 |
Why?
| | Venous Thrombosis | 1 | 2019 | 145 | 0.040 |
Why?
| | Thrombocytopenia | 1 | 2019 | 178 | 0.040 |
Why?
| | Peptides | 2 | 2013 | 849 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 184 | 0.030 |
Why?
| | Asia | 1 | 2016 | 53 | 0.030 |
Why?
| | Incidence | 1 | 2022 | 2324 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2017 | 200 | 0.030 |
Why?
| | Biological Products | 1 | 2019 | 171 | 0.030 |
Why?
| | Medicine | 1 | 2017 | 103 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1215 | 0.030 |
Why?
| | Policy Making | 1 | 2016 | 81 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2017 | 641 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 951 | 0.030 |
Why?
| | Hospitals | 1 | 2019 | 582 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2019 | 618 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2014 | 137 | 0.030 |
Why?
| | Cystatin C | 1 | 2014 | 62 | 0.030 |
Why?
| | Probability | 1 | 2014 | 290 | 0.030 |
Why?
| | Critical Illness | 1 | 2019 | 645 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 8658 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 501 | 0.030 |
Why?
| | Propylene Glycols | 1 | 2013 | 25 | 0.030 |
Why?
| | Sphingosine | 1 | 2013 | 33 | 0.030 |
Why?
| | Fingolimod Hydrochloride | 1 | 2013 | 30 | 0.030 |
Why?
| | Health Policy | 1 | 2016 | 333 | 0.030 |
Why?
| | Chronic Disease | 1 | 2018 | 1593 | 0.030 |
Why?
| | Vascular Calcification | 1 | 2014 | 107 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 130 | 0.030 |
Why?
| | Linear Models | 1 | 2014 | 779 | 0.030 |
Why?
| | Efficiency | 1 | 2012 | 84 | 0.030 |
Why?
| | Drug Evaluation | 1 | 2012 | 78 | 0.030 |
Why?
| | Health Services | 1 | 2012 | 103 | 0.020 |
Why?
| | Mitoxantrone | 1 | 2011 | 12 | 0.020 |
Why?
| | Hematologic Tests | 1 | 2011 | 22 | 0.020 |
Why?
| | Employment | 1 | 2012 | 139 | 0.020 |
Why?
| | Interferon-beta | 1 | 2011 | 79 | 0.020 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 87 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6157 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 523 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 929 | 0.020 |
Why?
| | Health Surveys | 1 | 2010 | 444 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 583 | 0.020 |
Why?
| | Electrocardiography | 1 | 2011 | 563 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2012 | 799 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1268 | 0.020 |
Why?
| | HIV Infections | 1 | 2014 | 2470 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3128 | 0.010 |
Why?
|
|
McQueen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|